Article

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials-05-01-2011
Volume20
Issue 5

Applied Clinical Trials Digital Edition - May 2011

eCLINICAL : Paperless IRB - Streamlined Efficiency Translating Data into Meaningful Metrics STATISTICS : Review of Categorical Data Analysis LABS : Industry Perspective of Good Clinical Laboratory Practice Also in this issue : Pharmaceutical R&D Funding, Europe 2020 Strategy, Protocol Amendments, Predicting Adverse Events

External Link - article-821539.pdf

Download Issue PDF
Articles in this issue
Applied Clinical Trials Digital Edition - May 2011
Applied Clinical Trials Digital Edition - May 2011, Supplement
i4-721604-1408619907188.gif
GCLP: an Industry Perspective
i1-719552-1408621802915.jpg
Innovation is in for EU's Healthcare System
i1_t-719557-1408621766993.gif
Study Completion Times
i4-719540-1408621872327.jpg
Business and News Update May 2011

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
How In-Home and Community Strategies Boost Recruitment and Diversity
August 20th 2025

How In-Home and Community Strategies Boost Recruitment and Diversity

Andy Studna, Senior Editor
ACT Brief Episode 4: New Data on Trial Delays, Hybrid Payment Models, and Managing Complexity
August 20th 2025

ACT Brief Episode 4: New Data on Trial Delays, Hybrid Payment Models, and Managing Complexity

Andy Studna, Senior Editor
Phase II Trial Demonstrates Encouraging Anti-Tumor Activity in Non-Small Cell Lung Cancer with sac-TMT
August 20th 2025

Phase II Trial Demonstrates Encouraging Anti-Tumor Activity in Non-Small Cell Lung Cancer with sac-TMT

Don Tracy, Associate Editor
ACT Brief Episode 3: Breaking Down Data Silos to Accelerate Clinical Trials
August 20th 2025

ACT Brief Episode 3: Breaking Down Data Silos to Accelerate Clinical Trials

Andy Studna, Senior Editor
Phase II Trial Data Lead to FDA Breakthrough Therapy Designation for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
August 20th 2025

Phase II Trial Data Lead to FDA Breakthrough Therapy Designation for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

Don Tracy, Associate Editor
© iDoPixBox - © iDoPixBox - stock.adobe.com
August 20th 2025

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan for EGFR-Mutated NSCLC

Andy Studna, Senior Editor
© 2025 MJH Life Sciences

All rights reserved.